This content is machine translated Follicular lymphoma Addition of tafasitamab significantly improves progression-free survival The results of the phase 3 study (inMIND) indicate a new treatment option for relapsed or refractory follicular lymphoma: The addition of tafasitamab to lenalidomide and rituximab significantly prolonged progression-free...…
View Post 4 min This content is machine translated From symptom to diagnosis Abdominal pain – Steatosis hepatis In steatotic liver diseases, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are distinguished from alcoholic fatty liver disease (AFLD) and alcoholic steatohepatitis (ASH) from an etiological point of…
View Post 4 min This content is machine translated Hematologic neoplasms Highlights and current data from the world of hematology ASH attendees immersed themselves in the world of hematology at the end of 2019. They learned about current trial data and findings around multiple myeloma, CAR-T cell therapy in LBCL,…
View Post 5 min This content is machine translated ASH in San Diego Pioneering study data on diffuse large B-cell lymphoma Among other things, new findings on the therapy of diffuse large B-cell lymphoma were presented. The phase III FLYER trial compared standard therapy (6xR-CHOP) with treatment reduced by two cycles…
View Post 8 min This content is machine translated ASH in Atlanta The throne wavers ECHELON-1 is the first positive data available on brentuximab vedotin in first-line Hodgkin lymphoma. And things are also progressing in CLL. Chemotherapy-free variants hold their own in recurrences.
View Post 5 min This content is machine translated ASH 2016 in San Diego Multiple Myeloma Review As every year, the ASH Congress took place in the busy pre-Christmas season. This time, experts from hematology and oncology met in San Diego. Multiple myeloma was again an important…
View Post 7 min This content is machine translated 57th ASH Meeting in Orlando New field of application for rituximab The ASH Congress was held last year in Orlando. This time, one of the topics was the efficacy of rituximab in adult patients with B-precursor acute lymphoblastic leukemia (ALL). Up…
View Post 3 min This content is machine translated HIV-associated lymphomas Stem cell transplantation is also a good therapy option for HIV patients At the ASH Congress in San Francisco, a study showed that HIV patients with relapsed or refractory lymphoma do not need to be treated differently than patients without HIV with…
View Post 4 min This content is machine translated Malignant hematological diseases One tablet – no chemotherapy Will there soon be a once-daily tablet that will eliminate the need for chemotherapy for malignant hematologic diseases such as acute myeloid leukemia? This question is being investigated in an…
View Post 4 min This content is machine translated Mantle cell lymphoma First- and second-line lenalidomide Mantle cell lymphoma (MZL) is an aggressive non-Hodgkin’s lymphoma that accounts for approximately 3-6% of all NHL cases. It has a poor prognosis, especially after failure of first-line therapy. Lenalidomide…
View Post 3 min This content is machine translated News from the ASH Congress on Nivolumab High response rates even in pretreated Hodgkin’s lymphomas Preclinical studies show that Sternberg-Reed cells, characteristic of classical Hodgkin lymphoma, use the PD-1 pathway to evade immunodetection. Therefore, immune checkpoint inhibitors such as nivolumab, which binds to the PD-1…
